IXC.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	INVEX Therapeutics Ltd (IXC.ASX)
Release Time	23 Jul 2026, 6:14 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

INVEX Therapeutics Ltd Q4 FY26 Operational and Financial Update

Key Points

Expanded preclinical research program with Tessara Therapeutics evaluating Exenatide
Cash and cash equivalents at quarter end were $4,016,000
Operating cash outflows for the quarter were $501,000

Full Summary

INVEX Therapeutics Ltd (ASX:IXC) has provided an operational and corporate update for the quarter ended 30 June 2026, as well as its Appendix 4C cash flow statement. The company announced the commencement of an expanded preclinical research program with Tessara Therapeutics, evaluating Exenatide and other GLP-1 receptor agonists in a three-dimensional Alzheimer's disease model. The program aims to benchmark Exenatide against a current GLP-1 agonist, evaluate combination regimens, and assess novel combinations. Financially, the company reported cash and cash equivalents of $4,016,000 at the end of the quarter, with operating cash outflows of $501,000, primarily due to increased research and development and administration costs.

Guidance

Operating cash outflows for Q4 FY26 were $501,000

Outlook

The company is optimistic about the potential of Exenatide in treating neurological conditions, particularly Alzheimer's disease, based on the results of the expanded preclinical research program.